Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation

Van Nguyen1, Tian Ming Tu2, Marlie Jane B. Mamauag3, Jovan Lai4, Seyed Ehsan Saffari2,5, Tar Choon Aw6, Lizhen Ong7, Roger S. Y. Foo8,9, Siang Chew Chai10, Shaun Fones1, Meifen Zhang11† and Troy H. Puar11*†

1 Doctor of Medicine Programme, Duke National University of Singapore (NUS) Medical School, Singapore, Singapore, 2 Department of Neurology, National Neuroscience Institute, Singapore, Singapore, 3 Department of Medicine, Neurology Division, Changi General Hospital (CGH), Singapore, Singapore, 4 Bachelor of Medicine, Bachelor of Surgery Programme, Yong Loo Lin School of Medicine, Singapore, Singapore, 5 Health Services and Systems Research, Duke–National University of Singapore (NUS) Medical School, Singapore, Singapore, 6 Department of Laboratory Medicine, CGH, Singapore, Singapore, 7 Department of Laboratory Medicine, National University Health System (NUHS), Singapore, Singapore, 8 Genome Institute of Singapore, Singapore, Singapore, 9 Cardiovascular Research Institute, NUHS, Singapore, Singapore, 10 Department of Cardiology, CGH, Singapore, Singapore, 11 Department of Endocrinology, CGH, Singapore, Singapore

Background: Primary aldosteronism (PA) is the most common cause of secondary hypertension, and patients are at an increased risk of atrial fibrillation (AF) and stroke. We assessed the prevalence of PA in patients with recent stroke.

Methods: We recruited 300 patients admitted to an acute stroke unit with diagnosis of cerebrovascular accident (haemorrhagic/ischaemic) or transient ischaemic attack. Three months post-stroke, plasma renin and aldosterone were measured. Patients with an elevated aldosterone–renin ratio proceeded to the confirmatory saline loading test.

Results: Twenty-six of 192 (14%) patients had an elevated aldosterone–renin ratio. Three of 14 patients who proceeded to saline loading were confirmed with PA (post-saline aldosterone >138 pmol/l). Another three patients were classified as confirmed/likely PA based on the markedly elevated aldosterone–renin ratio and clinical characteristics. The overall prevalence of PA amongst stroke patients with hypertension was 4.0% (95% confidence interval (CI): 0.9%–7.1%). Prevalence of PA was higher amongst patients with cardioembolic stroke, 11% (95% CI: 1.3%–33%), resistant hypertension, 11% (95% CI: 0.3%–48%), and hypertension and AF, 30% (95% CI: 6.7%–65%). If only young patients or those with hypokalaemia were screened for PA, half of our patients with PA would not have been diagnosed. Our decision tree identified that stroke patients with AF and diastolic blood pressure ≥83mmHg were most likely to have PA.

Conclusion: We found that amongst hypertensive patients with stroke, PA was more prevalent in those with AF, or cardioembolic stroke. Screening for PA should be considered for all patients with stroke.

Keywords: hyperaldosteronism, cerebrovascular accident, transient ischaemic attack, atrial fibrillation, secondary hypertension, endocrine hypertension
INTRODUCTION

Primary aldosteronism (PA) is the most common treatable cause of hypertension, affecting 5% of all patients with hypertension (1), and up to 25% amongst those with severe or resistant hypertension (2). Compared to patients with essential hypertension of similar blood pressure (BP), patients with PA are at a greater risk of renal and cardiovascular events (3, 4), due to the direct deleterious effects of aldosterone. Since hypertension is the most important risk factor for stroke (5), PA is likely as prevalent amongst patients with stroke.

Importantly, PA has been associated with increased risk of atrial fibrillation (AF), due to the presence of mineralocorticoid receptors on the myocardium (6, 7). A recent study by Seccia and colleagues found a prevalence of PA in 42% of hypertensive patients with unexplained AF, which may further compound the risk of stroke in PA (8). While hypertension is the main risk factor for both haemorrhagic stroke, and ischaemic strokes from large or small vessel disease (9), AF is the major risk factor for cardioembolic strokes (10).

Treatment of PA can ameliorate the risk of cardiovascular events, renal disease, and even improve quality of life, which underlies the importance of diagnosing and treating PA (11). Furthermore, patients with unilateral PA may be cured with surgery, leading to better outcomes compared with medical therapy (12, 13). There is currently no neurology consensus on which patients with stroke should be screened for secondary causes of hypertension. While some guidelines recommend screening young patients with stroke, the definition of a young age differs between guidelines (14). Current Endocrine Society guidelines recommend screening for PA in patients with severe or resistant hypertension, and those with family history of stroke below 40, but do not have a recommendation for patients with stroke (15). Hence, we hypothesized that PA is prevalent amongst patients with stroke and conducted a prospective trial in patients admitted with an acute stroke to assess the prevalence of PA.

METHODS

We prospectively recruited 300 patients admitted to the acute stroke unit of Changi General Hospital, Singapore, between August 2018 and October 2020. Inclusion criteria were age 21 to 80 years, diagnosis of transient ischaemic attack (TIA), or...
ischaemic/hemorrhagic acute cerebrovascular accident (CVA). Exclusion criteria were limited life expectancy (e.g., terminal illness), pregnancy, impaired renal function (estimated glomerular filtration rate (eGFR) <45 ml/min), and impaired cardiac function (ejection fraction 45% or lower). Chronic kidney disease was defined as eGFR <60 ml/min. Dyslipidemia was defined as LDL ≥1.8 mmol/l, or use of lipid-lowering medications. The study was approved by the local ethics committee, registered with Clinicaltrials.gov (NCT03789357), and informed consent was obtained in all patients. Baseline characteristics such as demographics, medical history, drug information, and comorbidities were collected.

Stroke Diagnosis and Management
All patients were managed for stroke in accordance with best clinical practice (16). Patients underwent further tests to determine the etiology of stroke, which included computed tomography or magnetic resonance imaging of the brain, ultrasound of carotid arteries, 2-dimensional transthoracic echocardiogram (2DE), and 24-h Holter monitoring as indicated. All of the above test results were reviewed independently by two investigators (VN, TT), and subtypes of stroke were classified based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Classification (17). Functional recovery status at 3 months or more were determined using the Modified Rankin Scale (MRS) (18).

BP Medications and Tests for PA
In the acute and post-acute management, choice of antihypertensive medications and BP targets were left to the managing neurologist, according to current treatment guidelines. Patients with newly diagnosed hypertension were started on first-line antihypertensive medications, usually angiotensin-converting enzyme (ACE) inhibitors or calcium-channel blockers. Two to four months post-stroke, all patients had a screening test, and plasma renin activity (PRA), and renal function. All blockers. Two to four months post-stroke, all patients had a converting enzyme (ACE) inhibitors or calcium-channel blockers. Two to four months post-stroke, all patients had a positive screening test underwent a confirmatory seated saline-loading test (SLT). Patients were confirmed with PA if post-saline PAC was >138 pmol/l or had spontaneous hypokalaemia with undetectable plasma renin activity (PRA) and PAC was >277 pmol/l (15). PAC and PRA were analysed by Mayo Clinic Laboratories, Rochester, MN, USA, for determination using LC-MS/MS, and the reference ranges were 0.6–3.0 ng/ml/h and 581 pmol/l or less, respectively, with the lowest level of detection 0.6 ng/ml/h and 110 pmol/l, respectively. For calculation of ARR, PRA was taken to be 0.6 ng/ml/h in those with undetectable PRA. Patients with PA were managed by an endocrinologist in accordance with the Endocrine Society guidelines.

Statistical Analysis
Statistical analysis was conducted using R (A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/). Continuous variables were expressed as a mean and standard deviation (SD) or median, minimum, and maximum or first and third quartile as appropriate and analysed using the independent-sample t-test or Mann–Whitney U test, depending on whether normality assumption was tenable. Categorical variables were presented as number (percent) and compared using the chi-squared test or Fisher exact test (where appropriate). The primary outcome was to determine the prevalence of PA in our cohort of patients with stroke. Secondary outcomes included the prevalence of PA in certain subgroups, and differences in characteristics of patients: those with PA versus those without PA, those with positive ARR versus negative ARR. A decision tree analysis via recursive partitioning for the classification method was performed to investigate how the baseline characteristics can help in discriminating patients with and without PA. Significance level was set at p value < 0.05.

RESULTS
From August 2018 to October 2020, 886 eligible patients were admitted with the primary diagnosis of TIA or CVA to the acute stroke unit (Figure 1). We recruited 300 patients, of which two patients were subsequently excluded from analysis as their final clinical diagnosis was not stroke and 106 patients were lost to follow-up (41 patients were uncontactable, 22 patients were discharged to primary care, 35 patients withdrew consent, five patients went overseas, three patients died). At 3 months post-stroke, 192 patients underwent ARR screening, median age 58.0 years, with 137 (71.4%) females (Table 1). Amongst 192 patients, 150 (78.1%) had hypertension, 55 (28.6%) had diabetes, 60 (31.3%) had history of smoking, and 24 (12.5%) had a previous stroke. Stroke subtypes were ischaemic in 156 (81.3%), haemorrhagic in 20 (10.4%), and TIA in 16 (8.3%) patients. Patients who underwent ARR screening were slightly younger (58.0 vs. 61.0 years, p = 0.03) compared to those who did not, but otherwise there were no other significant differences between the two groups (Supplementary Table 1).

Patients With Positive ARR
Twenty-six of 192 patients (14%) had a positive ARR screening test. The positive ARR group had higher diastolic blood pressure compared to the negative ARR group, 84.5 vs. 79.5 mmHg, p = 0.003, despite the similar number and type of antihypertensive medications (Table 2). Calcium-channel blockers and ACE inhibitors were the most commonly used. Patients with positive ARR were more likely to have AF, 19.2% vs. 3.0%, p = 0.005, and had greater left ventricular mass index (g/m²), 79.1 (69.8–99.8) vs. 67.8 (57.4–81.5), p = 0.02. There was no difference in stroke
subtype, and MRS score post-stroke between the groups. We repeated this analysis after restricting only to patients with hypertension (Supplementary Table 2) since hypertension may independently increase the risk of AF and left ventricular mass. We similarly found that hypertensive patients with positive ARR were more likely to have AF, 5 (21.7%) vs. 4 (3.2%), \( p = 0.005 \), and had greater left ventricular mass index (g/m²), 84.7 (69.9–101.1) vs. 68.9 (57.9–85.4), \( p = 0.016 \).

**Patients With PA**

Fourteen patients proceeded with confirmatory SLT, with three patients having post-SLT PAC >138 pmol/l, consistent with diagnosis of PA (Figure 1). Of the 12 patients who did not proceed with the confirmatory SLT test, five patients had poor cardiac or renal function (which developed/worsened after recruitment) which were contraindications to SLT, four were lost to follow-up, and three declined. One patient had baseline aldosterone \( \geq \)554 pmol/l, undetectable PRA, and spontaneous hypokalaemia and did not require additional tests to confirm PA. One patient was not able to undergo SLT due to poor cardiac function, and in view of repeated elevated ARRs (PAC 15 and 13 ng/dl, with undetectable renin), the patient was treated with spironolactone. One final patient had an inappropriate PAC (7.9 ng/dl) and undetectable renin despite being on an ACE inhibitor. Due to newly diagnosed AF and impaired cardiac function, spironolactone was started with clinical improvement. In total, six patients had confirmed or likely PA. All six were treated with spironolactone and did not pursue subtype testing: one patient migrated, three patients declined surgery (two were \( \geq \)65 years), and two were subsequently diagnosed with cardiac or renal impairment which made them poor surgical candidates.

All six patients with PA had hypertension, three had AF, and two had hypokalaemia. Patients with PA had a higher diastolic BP at the 3-month follow-up (87.0 vs. 80.0 mmHg, \( p = 0.01 \)) and were more likely to use calcium-channel blockers (83.5% vs. 36.6%, \( p = 0.03 \)), and the median number of BP medications used was 1.7 vs. 1.0, \( p = 0.06 \) (Table 3). Patients with PA were more likely to have AF (50% vs. 3.8%, \( p = 0.002 \)) compared to those without PA. Patients with PA had a higher left ventricular mass index (g/m²), 90.7 vs. 69.2, \( p = 0.01 \), and were more likely to have left atrial dilatation (defined as left atrial volume index >34 ml/m²), 50.0% vs. 11.8%, \( p = 0.03 \).

The prevalence of PA in the cohort was 3.1%, 95% CI: 1.2%–6.7%, amongst all patients, and 4.0%, 95% CI: 0.9%–7.1%, amongst patients with hypertension (Figure 2). Prevalence rates were higher in subgroups: age \( \leq \)50 years, 6.1% (3 of 49), 95% CI: 1.3%–16.9%, cardioembolic strokes, 10.5% (2 of 19), 95% CI: 1.3%–33.1%, resistant hypertension, 11.1% (1 of 9), 95% CI: 0.3%–48.3%, hypertension with hypokalaemia, 13.3% (2 of 15), 95% CI: 1.7%–40.5%, hypertension and AF, 30.0% (3 of 10), 95% CI: 6.7%–65.3%.

**Decision Tree Algorithm**

Our decision tree algorithm was derived from the 192 patients for whom complete data existed for all predictor and outcome variables, and it identified two main factors: diastolic BP and presence of AF. Patients with a diastolic BP \( \geq \)83 mmHg were more likely to have PA, and this increased to 100% amongst those with both diastolic BP \( \geq \)83 mmHg and presence of AF at 3 months post-stroke (Figure 3). In the 169 patients with 2D-echocardiography data, the decision tree algorithm yielded similar results.
TABLE 1 | Baseline characteristics of patients who completed the screening aldosterone-renin-ratio test.

| Baseline characteristics | N = 192 |
|--------------------------|---------|
| **Demographics**         |         |
| Age, years               | 58.0 [21.0, 78.0] |
| Male                     | 137 [71.4] |
| Body mass index, g/m²    | 25.5 [13.8, 45.7]; N = 183 |
| Potassium, mmol/L        | 4.0 [2.9, 5.8] |
| Estimated glomerular filtration rate, mL/min/1.73 m² | 94.6 [41.3, 130] |
| Systolic blood pressure, mmHg | 157 [80, 247]; N = 187 |
| Diastolic blood pressure, mmHg | 90 [51, 142]; N = 187 |
| Serum aldosterone, pmol/L | 156 [38, 1,551] |
| Plasma renin activity, ng/ml/h | 1.7 [0.6, 24.0] |
| Aldosterone-renin ratio, pmol/L per ng/ml/h | 122 [6, 922] |

**Comorbidities**

- Hypertension: 150 (78.1)
- Diabetes: 55 (28.6)
- Dyslipidaemia: 192 (100)
- History of smoking: 60 (31.3)
- History of drinking: 34 (17.7)
- Ischaemic heart disease: 27 (14.1)
- Atrial fibrillation: 10 (5.2)
- Chronic kidney disease: 15 (7.8)
- Stroke history: 24 (12.5)

**Stroke subtypes**

- Ischaemic stroke: 156 (81.3)
- Small-artery occlusion: 50 (26.0)
- Large-artery atherosclerosis: 25 (13.0)
- Cardioembolic: 19 (10.0)
- Undetermined: 62 (32.3)
- Haemorrhagic stroke: 20 (10.4)
- Transient ischaemic attack: 16 (8.3)

**Modified Rankin Scale Score**

- 1.2 (1.4); N = 183

**Use of antihypertensive medication**

- ACE-inhibitor or angiotensin II receptor blocker: 69 (35.9)
- Beta-blocker: 46 (24.0)
- Calcium channel blocker: 73 (38.0)
- Diuretics: 2 (1.0)
- Alpha blocker: 1 (0.5)
- Number of antihypertensive medication: 1.0 (0.91)

**2D echocardiogram parameters**

- Left ventricular ejection fraction, %: 60.0 [15.0, 66.0]; N = 169
- Presence of left ventricular hypertrophy: 9 (5.33%); N = 169
- Relative wall thickness, h/r: 0.4 [0.2, 0.7]; N = 165
- Left atrium volume index, ml/m²: 24.4 [13.2, 134]; N = 162
- Left ventricular mass index, m²: 69.8 [39.3, 173]; N = 164

Data presented as median [min, max], mean (SD), or number (%) as appropriate.

**DISCUSSION**

In our prospective cohort study, PA was prevalent in at least 4% of hypertensive patients with stroke, which increased to 11% amongst those with cardioembolic stroke and 30% amongst those with atrial fibrillation. There has been a growing body of evidence that PA is associated with increased risk of AF (7, 13), and our study identifies another high-risk group of patients that should be screened for PA, namely those with cardioembolic stroke, or stroke with concomitant atrial fibrillation. We also found that patients with PA or elevated ARR had a greater left ventricular mass index, which highlights the deleterious effects of hyperaldosteronism, as well as importance of appropriate diagnosis and treatment of PA.

AF is the main predisposing factor for embolic strokes, which accounts for 15%–20% of all strokes (19). Excessive aldosterone is a major contributor to AF pathogenesis by inducing both structural cardiac remodelling through atrial dilatation and fibrosis, and electrical remodelling through arrhythmogenicity (20, 21). In our study, patients with positive ARR had higher rates of AF and greater left ventricular mass index compared to those with negative ARR, suggesting that the effects of hyperaldosteronism may not be restricted only to patients with PA, as has been previously reported (22). Patients with elevated ARR are particularly responsive to mineralocorticoid antagonists. Hence, patients with elevated ARR but normal response to saline suppression (false-positive ARR) may still benefit from therapy with spironolactone, similar to patients with PA (23). In addition, our patients with PA had a larger left atrial volume index, which predisposes to development of AF. Milliez and colleagues found a 12-fold higher risk of prevalent AF amongst patients with PA (6), compared to patients with essential hypertension, which has been supported by subsequent studies (24). Most recently, Seccia and colleagues found a high prevalence of PA in 42% of hypertensive patients with unexplained AF (8), which is not dissimilar from our prevalence of 30% amongst hypertensive patients with AF and stroke. Hence, our study confirms findings from previous studies that patients with PA are at a higher risk of stroke. Of particular note, one of our patients with PA was classified as embolic stroke of undetermined source (ESUS), because repeated cardiac monitoring (24-h Holter and extended 28-day Spyder) did not reveal any episodes of AF. ESUS may be attributed to various potential embolic sources, including occult atrial cardiopathy, and some patients may go on to develop AF (25). Hence, it is plausible that PA may be similarly common amongst patients with ESUS, and these patients should be offered screening for PA.

Hypertension is the main risk factor for haemorrhagic strokes, as well as ischaemic strokes from small- or large-vessel disease (9). Patients with PA have a 4–5-fold greater odds of stroke compared to patients with essential hypertension (6, 26), which is attributed to the deleterious effects of aldosterone on cerebral vasculature through oxidative stress and endothelial dysfunction (27). In our cohort, patients with either elevated ARR or PA had a greater left ventricular mass index, which underlines the effects of hyperaldosteronism on the myocardium (28). While all of our PA patients had hypertension, less than half had hypokalaemia, or were aged below 50 years, highlighting that hypokalaemia and age thresholds should not be prerequisites to screen for PA. One previous study on young stroke patients (below 45 years) found the prevalence rate of PA to be 12% (21). If we restricted screening to patients below 45 years of age, we would have only diagnosed one patient. Miyaji and colleagues found the prevalence of PA to be 4% amongst a cohort of patients with recent stroke, and 4.9% when restricted to those with hypertension, but did not report on the prevalence of AF (29). In their study, patients were screened for PA in the first 2 weeks post-stroke, which is not ideal as malignant hypertension or acute illness may alter PAC and PRA, and cosyntropin
stimulation was used as a confirmatory test for PA, which is not currently recommended by guidelines (15).

Our findings suggest that all patients with previous stroke may benefit from screening for PA. Treatment of PA has been shown to reduce the risk of developing AF, cardiovascular, and cerebrovascular diseases (30). Although earlier studies found both surgical and medical therapy equally effective, more recent data suggest that surgical treatment leads to better outcomes (12, 13). None of our patients underwent subtype testing with adrenal vein sampling and surgery, similar to previous studies (29, 31), due to poor functional status or comorbidities in the patients. This emphasizes the importance of early diagnosis of PA, which unfortunately remains suboptimal, with less than 1% of all patients at risk of PA being screened (32). Early diagnosis and treatment of PA reduces target organ damage and increases the likelihood of cure of hypertension (33, 34). While patients diagnosed with PA post-stroke may not be good candidates for surgery, they are at high cardiovascular risk and can still benefit from aldosterone antagonists. Eplerenone treatment has been shown in animal models to reduce the aldosterone-induced damage to the cerebral cortex (35). In our retrospective cohort, 14 of our 154 (9%) patients with PA had a prior diagnosis of CVA (36). Hence, while there should be sustained efforts in the early diagnosis and

| TABLE 2 | Characteristics of patients with positive ARR (N = 26) versus patients with negative ARR (N = 166). |
|----------------|---------------------------------|-----------------|------------------|-----------------|
| Characteristics | Patients with ARR + N = 26 (13.5%) | Patients with ARR− N = 166 (86.5%) | p value |
| Demographics | | | |
| Age, years | 56.0 [47.5, 63.5] | 58.0 [51.0, 64.1] | 0.43 |
| Male | 16 (61.5) | 121 (72.9) | 0.25 |
| Body mass index, g/m² | 25.6 [25.0, 27.0] | 25.5 [23.0, 28.3] | N = 157 | 0.76 |
| Systolic blood pressure, mmHg | 145 [133, 146] | 137 [125, 149] | N = 162 | 0.11 |
| Diastolic blood pressure, mmHg | 84.5 [80.0, 92.0] | 79.5 [74.0, 85.0] | N = 162 | 0.003 |
| Estimated glomerular filtration rate, mL/min/1.73 m² | 94.3 [78.1, 100] | 94.6 [82.5, 104] | N = 162 | 0.56 |
| Sodium, mmol/L | 140 [139, 142] | 140 [138, 141] | 0.17 |
| Potassium, mmol/L | 3.9 [3.6, 4.1] | 4.0 [3.7, 4.2] | 0.25 |
| Bicarbonate, mmol/L | 23.0 [22.0, 25.8] | 23.0 [21.0, 24.0] | N = 162 | 0.26 |
| Total cholesterol mmol/L | 4.8 [4.1, 5.3] | 4.7 [3.9, 5.4] | N = 158 | 0.62 |
| LDL mmol/L | 3.2 [2.8, 3.8] | 3.2 [2.6, 3.8] | N = 158 | 0.73 |
| HBA1C, % | 5.9 [5.5, 6.7] | 6.1 [5.5, 7.1] | N = 161 | 0.37 |
| Serum aldosterone, pmol/L | 269 [213, 410] | 139 [111, 223] | N = 15 | <0.001 |
| Plasma renin activity, ng/ml/h | 0.60 [0.60, 0.78] | 1.96 [0.90, 3.38] | N = 161 | <0.001 |
| Aldosterone-renin-ratio, pmol/L per ng/ml/h | 355 [321, 452] | 108 [47, 186] | N = 161 | <0.001 |
| Comorbidities | | | |
| Hypertension | 23 (88.5) | 127 (76.5) | 0.21 |
| Diabetes mellitus | 7 (26.9) | 48 (29.3) | 1.0 |
| Dyslipidaemia | 26 (100) | 166 (100) | 1.0 |
| History of smoking | 7 (26.9) | 53 (31.7) | 0.82 |
| History of drinking | 4 (15.4) | 30 (18.3) | 1.0 |
| Ischaemic heart disease | 4 (15.4) | 23 (14.0) | 0.77 |
| Atrial fibrillation | 5 (19.2) | 5 (3.0) | 0.0005 |
| Chronic kidney disease | 3 (11.5) | 12 (7.2) | 0.44 |
| Stroke history | 1 (3.9) | 23 (13.9) | 0.21 |
| Stroke subtypes | | | |
| Ischaemic stroke | 23 (88.5) | 133 (80.1) | 0.78 |
| Undetermined | 9 (34.6) | 53 (31.9) | |
| Others | 14 (53.9) | 82 (48.2) | 0.0005 |
| Haemorrhagic stroke | 2 (7.7) | 18 (10.8) | 0.03 |
| Transient ischaemic attack | 1 (3.9) | 15 (9.0) | 0.03 |
| Modified Rankin Scale Score | 0.92 (1.3) | 1.2 (1.4) | 0.33 |
| Antihypertensive medication | | | |
| ACE-inhibitor or Angiotensin II receptor blocker | 8 (30.8) | 61 (36.7) | 0.66 |
| Beta-blocker | 8 (30.8) | 38 (22.9) | 0.46 |
| Calcium channel blocker | 12 (46.2) | 61 (36.7) | 0.39 |
| Diuretics | 1 (3.9) | 1 (0.60) | 0.25 |
| Alpha blocker | 1 (3.9) | 0 (0) | 0.14 |
| Number of antihypertensive medication | 1.2 (1.2) | 1.0 (0.86) | 0.75 |
| 2D echocardiogram parameters | | | |
| Left ventricular ejection fraction, % | 60.0 [55.0, 60.0] | 60.0 [55.0, 60.0] | N = 15 | 0.62 |
| Presence of left ventricular hypertrophy | 3 (12.0) | 6 (4.2) | N = 144 | 0.13 |
| Relative wall thickness, h/r | 0.42 [0.35, 0.48] | 0.40 [0.34, 0.45] | N = 140 | 0.37 |
| Left atrium volume index, ml/m² | 25.7 [22.2, 30.0] | 24.0 [19.7, 28.5] | N = 139 | 0.25 |
| Left ventricle mass index, m² | 79.1 [69.8, 99.9] | 76.8 [67.4, 81.5] | N = 139 | 0.016 |

Data presented as median [min, max], mean (SD), or number (%) as appropriate. ARR, aldosterone–renin ratio.

Nguyen et al. | Primary Aldosteronism in Stroke Patients

Frontiers in Endocrinology | www.frontiersin.org | April 2022 | Volume 13 | Article 869980


treatment of PA, the event of a stroke should prompt clinicians to consider screening for secondary causes, particularly in patients with good functional recovery.

We recognize several limitations of our study. First, as our number of patients diagnosed with PA was small, we included 95% CI to reflect the strength of our prevalence estimates. Second, one-third of patients enrolled did not undergo a screening test. However, their baseline characteristics did not differ greatly from patients who proceeded with screening and are unlikely to affect our estimates. Third, not all patients with a positive screening test proceeded with a confirmatory SLT, due to cardiac or renal dysfunction. Hence, there are likely more patients with PA and a higher prevalence of PA. Fourth, a single PAC assessment may not fully reflect aldosterone status, and studies using 24-h urinary aldosterone have found a higher prevalence of PA (2). Finally, ARR can be affected by use of antihypertensive medications, such as ACE inhibitors and diuretics, leading to false-negative results (15). To reduce false-negative screening rates, we adopted a lower ARR threshold for case detection. Furthermore, other studies have similarly screened for PA with these medications on-board (1), and we had to avoid changing antihypertensive medications soon after a recent stroke as stringent BP control is of critical importance (37). Despite these known limitations when screening patients with stroke (38), we were able to diagnose a significant proportion of patients with PA. This underlies the fact that PA is common and often missed early on in its natural history. Following the call that more patients with stroke should be screened for PA (38), our study offers clinicians a feasible strategy to do so.

In conclusion, we found PA to be prevalent in patients with a recent stroke, similar to cohorts of hypertensive patients, and particularly higher in those with cardioembolic stroke, and concomitant AF. Restricting screening of PA to young patients or those with hypokalaemia would have missed a majority of patients with PA. Hence, we suggest screening all hypertensive patients with stroke for PA as a possible underlying cause, particularly if they have good functional recovery. The impetus

### TABLE 3 | Characteristics of patients with primary aldosteronism (N = 6) versus patients without primary aldosteronism (N = 186).

| Characteristics                     | Patients with PA N = 6 | Patients without PA N = 186 | p value |
|-------------------------------------|------------------------|-----------------------------|---------|
| **Demographics**                    |                        |                             |         |
| Age, years                          | 57.3 [44.5, 65.9]      | 58.0 [51.0, 64.0]           | 0.91    |
| Male N (%)                          | 4 (66.7)               | 133 (71.5)                  | 1.0     |
| Body mass index, g/m²               | 24.8 [21.8, 27.4]      | 25.5 [23.0, 28.2] N = 177   | 0.58    |
| Systolic blood pressure, mmHg       | 146 [138, 147]         | 137 [126, 149] N = 182      | 0.36    |
| Diastolic blood pressure, mmHg      | 87.0 [84.3, 92.8]      | 80.0 [74.0, 86.0] N = 182   | 0.011   |
| Estimated glomerular filtration rate, mL/min/1.73 m² | 78.2 [66.1, 89.6] | 94.9 [82.5, 103] | 0.060 |
| Serum aldosterone, pmol/L           | 416 [271, 521]         | 150 [111, 238] N = 0.0014   |
| Plasma renin activity, ng/ml/h      | 0.65 [0.60, 1.15]      | 1.7 [0.7, 3.2] N = 0.048    |
| Aldosterone-renin ratio, pmol/L per ng/ml/h | 343 [319, 609] | 116 [53, 188] <0.001 |
| **Comorbidities**                   |                        |                             |         |
| Hypertension                        | 6 (100)                | 144 (77.4)                  | 0.34    |
| Diabetes mellitus                   | 2 (33.3)               | 53 (28.5)                   | 1.0     |
| Dyslipidaemia                        | 6 (100)                | 186 (100)                   | 1.0     |
| History of smoking                  | 2 (33.3)               | 58 (31.2)                   | 1.0     |
| History of drinking                 | 0 (0)                  | 34 (18.3)                   | 0.59    |
| Ischaemic heart disease             | 1 (16.7)               | 26 (14.0)                   | 1.0     |
| Atrial fibrillation                  | 3 (50.0)               | 7 (3.8)                     | 0.0019  |
| Chronic kidney disease              | 1 (16.7)               | 14 (7.5)                    | 0.39    |
| Stroke history                       | 0 (0)                  | 24 (12.9)                   | 1.0     |
| **Stroke subtypes**                 |                        |                             |         |
| Ischaemic stroke                     | 6 (100)                | 150 (80.6)                  | 1.0     |
| Undetermined                         | 2 (33.3)               | 60 (32.3)                   | 1.0     |
| Others                               | 4 (66.7)               | 90 (67.7)                   | 1.0     |
| Haemorrhagic stroke                  | 0 (0)                  | 20 (10.8)                   | 1.0     |
| Transient ischaemic attack           | 0 (0)                  | 16 (8.6)                    | 1.0     |
| **Modified Rankin Scale Score**     | 0.33 (0.82)            | 1.2 (1.4) N = 178           | 0.10    |
| **Antihypertensive medication**     |                        |                             |         |
| ACE-inhibitor or angiotensin II receptor blocker | 2 (33.3) | 67 (36.0) | 1.0     |
| Beta-blocker                         | 3 (60.0)               | 43 (23.1)                   | 0.15    |
| Calcium channel blocker              | 5 (83.3)               | 68 (36.6)                   | 0.030   |
| Diuretics                            | 0 (0)                  | 2 (1.1)                     | 1.0     |
| Alpha blocker                        | 0 (0)                  | 1 (0.5)                     | 1.0     |
| Number of anti-HTN meds, mean       | 1.7 (0.82)             | 1.0 (0.9)                   | 0.06    |
| **2D echocardiogram parameters**   |                        |                             |         |
| Left ventricular ejection fraction, % | 52.5 [30.0, 60.0] | 60.0 [55.0, 60.0] N = 163 | 0.11    |
| Presence of left ventricular hypertrophy | 0 (0) | 9 (5.5) N = 163 | 1.0     |
| Relative wall thickness, h/r         | 0.41 [0.33, 0.42]      | 0.40 [0.35, 0.45] N = 159   | 0.61    |
| Left atrium volume Index, ml/m²      | 31.2 [25.6, 44.0]      | 24.0 [19.8, 28.2]           | 0.032   |
| Left ventricular mass index, m²      | 90.7 [83.9, 102]       | 69.2 [57.9, 83.7]           | 0.012   |

Data presented as median [min, max], mean (SD), or number (%) as appropriate.
PA, primary aldosteronism.
for screening these patients is that appropriate diagnosis and treatment can ameliorate BP control, potentially identify a treatable and potentially curable cause of hypertension, and prevent a recurrent stroke, which may be catastrophic.

**Perspectives**
Current guidelines recommend screening for PA in patients with severe or resistant hypertension, and hypertension with hypokalaemia. Our study supports the increasing call that presence of AF should be included as another indication for screening. In addition, patients with previous strokes are more likely to have PA. While these patients may not be ideal candidates for surgical treatment, they are at a high cardiovascular risk, and specific medical treatment for hyperaldosteronism is warranted. Early diagnosis and treatment for all patients with PA are the ultimate goal.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article can be made available by the authors upon request.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by SingHealth Institutional Review Board. The studies involving human participants were reviewed and approved by the Chiang Health Fund (CHF2017.01-P and CHF2020.05-S to MZ).

AUTHOR CONTRIBUTIONS
VN, SS, and TP had full access to the data in the study and take responsibility of the integrity of the data and accuracy of data analysis. TT, MM, JL, MZ, and TP recruited patients in the study and performed the data collection. TT, TA, LO, SF, MZ, and TP worked on the study concept and design. VN, TT, SF, and TP were involved in drafting of the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Käyser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab (2016) 101(7):2826–35. doi: 10.1210/jc.2016-1472
2. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The Unrecognized Prevalence of Primary Aldosteronism. Ann Intern Med (2020) 173(1):10–20. doi: 10.7326/M20-0065
3. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism. Hypertension (2013) 62(1):62–9. doi: 10.1161/HYPERTENSIONAHA.113.03136.
4. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal Damage in Primary Aldosteronism: Results of the PAPY Study. Hypertension (2006) 48(2):232–8. doi: 10.1161/01.HYP.0000230444.01215.6a
5. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk Factors for Ischaemic and Intracerebral Haemorrhagic Stroke in 22 Countries (the INTERSTROKE Study): A Case-Control Study. Lancet (2010) 376(9735):112–23. doi: 10.1016/S0140-6736(10)60834-3
6. Milliez P, Gireux X, Plouin P-F, Blacher J, Safar ME, Mourad J-J. Evidence for an Increased Rate of Cardiovascular Events in Patients With Primary Aldosteronism. J Am Coll Cardiol (2005) 45(8):1243–8. doi: 10.1016/j.jacc.2005.01.015
7. Savard S, Amar L, Plouin P-F, Steichen O. Cardiovascular Complications Associated With Primary Aldosteronism: A Controlled Cross-Sectional Study. Hypertension (2013) 62(2):331–6. doi: 10.1161/HYPERTENSIONAHA.113.01060
8. Seccia TM, Letizia C, Muesan ML, Lerco S, Cesari M, Bisogni V, et al. Atrial Fibrillation as Presenting Sign of Primary Aldosteronism: Results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J Hypertens (2020) 38(2):332–9. doi: 10.1097/HJH.0000000000002250
9. Ohiro T, Shahar E, Chambless Lloyd E, Rosamond Wayne D, Mosley Thomas H, Folsom Aaron R. Risk Factors for Ischemic Stroke Subtypes. Stroke (2006) 37(10):2493–8. doi: 10.1161/01.STR.0000239694.19359.88
10. Kamel H, Healey JS. Cardioembolic Stroke. Circ Res (2017) 120(3):514–26. doi: 10.1161/CIRCRESAHA.116.308407
11. Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, et al. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalec tomy and Medical Treatment. J Clin Endocrinol Metab (2018) 103(1):16–24. doi: 10.1210/jc.2017-01442
12. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic Outcomes and Mortality in Medically Treated Primary Aldosteronism: A Retrospective Cohort Study. Lancet Diabetes Endocrinol (2018) 6(1):51–9. doi: 10.1016/S2213-8587(17)30367-4
13. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol (2018) 3(8):768–74. doi: 10.1001/jamacardio.2018.2003
14. Yahya T, Jilani MH, Khan SU, Mszar R, Hassan SZ, Bhaia MJ, et al. Stroke in Young Adults: Current Trends, Opportunities for Prevention and Pathways Forward. Am J Prev Cardiol (2020) 3:100085. doi: 10.1016/j.ajpc.2020.100085
15. Funder JW, Ramires RM, Munera M, Mirand M, Reimcke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2016) 101(5):1889–916. doi: 10.1210/jc.2015-4061
16. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke (2021) 52:e344–e418. doi: 10.1161/STR.119.100000000000211
17. Adams HP, Bendixen BH, Kappelle LI, Biller J, Love BB, Gordon DL, et al. Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke (1993) 24(1):35–41. doi: 10.1161/01.str.24.1.35
18. Rankin J. Cerebral Vascular Accidents in Patients Over the Age of 60. II. Prognosis. Scott Med J (1957) 2(5):200–15. doi: 10.1177/003693305700200504
19. Penado S, Cano M, Acha O, Hernández JL, Riancho JA. Atrial Fibrillation as a Risk Factor for Stroke Recurrence. Am J Med (2003) 114(3):206–10. doi: 10.1016/S0002-9343(02)01479-1
20. Pan C-T, Tsai C-H, Chen Z-W, Chang Y-Y, Wu V-C, Hung C-S, et al. Atrial Fibrillation in Primary Aldosteronism. Horm Metab Res (2020) 52(6):357–65. doi: 10.1055/a-1141-5989
21. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of Aldosterone Antagonists on the Substrate for Atrial Fibrillation: Aldosterone Promotes Oxidative Stress and Atrial Structural/Electrical Remodeling. Int J Cardiol (2013) 168(6):5135–42. doi: 10.1016/j.jcc.2013.08.022

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.869980/full#supplementary-material
22. Choi E-Y, Ha J-W, Yoon S-J, Shim C-Y, Seo H-S, Park S, et al. Increased Plasma Aldosterone-to-Renin Ratio is Associated With Impaired Left Ventricular Longitudinal Functional Reserve in Patients With Uncomplicated Hypertension. *J Am Soc Echocardiogr* (2008) 21(3):251–6. doi: 10.1016/j.echo.2007.08.005

23. Lim PO, Jung RT, MacDonald TM. Raised Aldosterone to Renin Ratio Predicts Antihypertensive Efficacy of Spironolactone: A Prospective Cohort Follow-Up Study. *Br J Clin Pharmacol* (1999) 48(5):756–60. doi: 10.1046/j.1365-2125.1999.00070.x

24. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular Events and Target Organ Damage in Primary Aldosteronism Compared With Essential Hypertension: A Systematic Review and Meta-Analysis. *Lancet Diabetes Endocrinol* (2018) 6(1):41–50. doi: 10.1016/S2213-8587(17)30319-4

25. Ntaios G. Embolic Stroke of Undetermined Source. *J Am Coll Cardiol* (2020) 75(3):333–40. doi: 10.1016/j.jacc.2019.11.024

26. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment. *Arch Intern Med* (2008) 168(1):80–5. doi: 10.1001/archinternmed.2007.33

27. Chen ZW, Hung CS, Wu VC, Lin YHT. *AIPAI study group. Primary Aldosteronism and Cerebrovascular Diseases. Endocrinol Metab (Seoul)* (2018) 33(4):429–34. doi: 10.3803/EnM.2018.33.4.429

28. Cuspidi C, Tadic M, Sala C, Quarti-Trevano F, Gherbesi E, Mancia G, et al. Regression of Left Ventricular Hypertrophy in Primary Aldosteronism After Adrenalectomy: A Meta-Analysis of Echocardiographic Studies. *J Hypertens* (2020) 39(4):775–83. doi: 10.1097/HJH.0000000000002679

29. Miyaji Y, Kawabata Y, Joki H, Seki S, Mori K, Kamide T, et al. Primary Aldosteronism in Patients With Acute Stroke: Prevalence and Diagnosis During Initial Hospitalization. *BMC Neurol* (2016) 16(1):177. doi: 10.1186/s12883-016-0701-5

30. Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, et al. Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. *Hypertension* (2018) 71(4):585–91. doi: 10.1161/HYPERTENSIONAHA.117.10596

31. Tang Z, Chen H, He W, Ma L, Song Y, Mei M, et al. Primary Aldosteronism in Young Adults With Acute Stroke: Prevalence and Clinical Characteristics. *J Neurol Sci* (2020) 413:116774. doi: 10.1016/j.jns.2020.116774

32. Liu Y-Y, King I, Kline GA, Padwal RS, Pasieka JL, Chen G, et al. Outcomes of a Specialized Clinic on Rates of Investigation and Treatment of Primary Aldosteronism. *JAMA Surg* (2021) 156(6):541–9. doi: 10.1001/jamasurg.2021.0254

33. Zarnegar R, Young WF, Lee J, Sweet MP, Kebebew E, Farley DR, et al. The Aldosteronoma Resolution Score: Predicting Complete Resolution of Hypertension After Adrenalectomy for Aldosteronoma. *Ann Surg* (2008) 247(3):511–8. doi: 10.1097/SLA.0b013e318165c075

34. Morisaki M, Kurihara I, Itoh H, Naruse M, Takeda Y, Katabami T, et al. Predictors of Clinical Success After Surgery for Primary Aldosteronism in the Japanese Nationwide Cohort. *J Endocr Soc* (2019) 3(11):2012–22. doi: 10.1210/js.2019-00295

35. Wang X, Zhu Y, Wang S, Wang Z, Sun H, He Y, et al. Effects of Eplerenone on Cerebral Aldosterone Levels and Brain Lesions in Spontaneously Hypertensive Rats. *Clin Exp Hypertens* (2020) 42(6):531–8. doi: 10.1080/10641963.2020.1723615

36. Puar TH, Loh LM, Loh WJ, Lim DST, Zhang M, Tan PT, et al. Outcomes in Unilateral Primary Aldosteronism After Surgical or Medical Therapy. *Clin Endocrinol (Oxf)* (2020) 94(2):158–67. doi: 10.1111/cen.14351

37. Lackland DT, Roccella EJ, Deutsch A, Fornage M, George MG, Howard W, et al. Factors Influencing the Decline in Stroke Mortality. *Stroke* (2014) 45(1):315–53. doi: 10.1161/01.str.0000437068.30550.cf

38. McCarthy J, Yang J, Clissold B, Young MJ, Fuller PJ, Phan T. Hypertension Management in Stroke Prevention: Time to Consider Primary Aldosteronism. *Stroke* (2021) 52(10):e626–34. doi: 10.1161/STROKEAHA.120.033990

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Nguyen, Xu, Mamauag, Lai, Safiari, Aw, Ong, Foo, Chai, Fones, Zhang and Puar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.